42 related articles for article (PubMed ID: 38428066)
1. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
[TBL] [Abstract][Full Text] [Related]
2. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
Zheng J; Qin C; Wang Q; Tian D; Chen Z
EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
[TBL] [Abstract][Full Text] [Related]
4. Evaluating personalized circulating tumor DNA detection for early-stage lung cancer.
Huang H; Kai Z; Wang Y; Zhang X; Wang J; Zhang W; Xue Q; Zhang H; Jin H; Meng P; Zhang S; Yang Y; Yang H; Liang W; Zha G; Luo P; Xu Y; Shi W; Ruan Z
Cancer Med; 2024 May; 13(10):e6817. PubMed ID: 38112031
[TBL] [Abstract][Full Text] [Related]
5. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
Shaw JA; Page K; Wren E; de Bruin EC; Kalashnikova E; Hastings R; McEwen R; Zhang E; Wadsley M; Acheampong E; Renner D; Gleason KLT; Ambasager B; Stetson D; Fernandez-Garcia D; Guttery D; Allsopp RC; Rodriguez A; Zimmermann B; Sethi H; Aleshin A; Liu MC; Richards C; Stebbing J; Ali S; Rehman F; Cleator S; Kenny L; Ahmed S; Armstrong AC; Coombes RC
JCO Precis Oncol; 2024 Apr; 8():e2300456. PubMed ID: 38691816
[TBL] [Abstract][Full Text] [Related]
6. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T; Takao S; Dairaku K; Uno N; Low SA; Hashimoto M; Tsuda Y; Hisamatsu Y; Toshima T; Yonemura Y; Masuda T; Eto K; Ikegami T; Fukunaga Y; Niida A; Nagayama S; Mimori K
Cancer Sci; 2024 Jun; 115(6):1989-2001. PubMed ID: 38531808
[TBL] [Abstract][Full Text] [Related]
7. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Early Hospice or Death in Patients With Inoperable Lung Cancer Treated With Curative Intent.
Ramanathan S; Hochstedler KA; Laucis AM; Movsas B; Stevens CW; Kestin LL; Dominello MM; Grills IS; Matuszak M; Hayman J; Paximadis PA; Schipper MJ; Jolly S; Boike TP;
Clin Lung Cancer; 2024 Jun; 25(4):e201-e209. PubMed ID: 38290875
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
[TBL] [Abstract][Full Text] [Related]
10. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Abbosh C; Birkbak NJ; Wilson GA; Jamal-Hanjani M; Constantin T; Salari R; Le Quesne J; Moore DA; Veeriah S; Rosenthal R; Marafioti T; Kirkizlar E; Watkins TBK; McGranahan N; Ward S; Martinson L; Riley J; Fraioli F; Al Bakir M; Grönroos E; Zambrana F; Endozo R; Bi WL; Fennessy FM; Sponer N; Johnson D; Laycock J; Shafi S; Czyzewska-Khan J; Rowan A; Chambers T; Matthews N; Turajlic S; Hiley C; Lee SM; Forster MD; Ahmad T; Falzon M; Borg E; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Hafez D; Naik A; Ganguly A; Kareht S; Shah R; Joseph L; Marie Quinn A; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Oukrif D; Akarca AU; Hartley JA; Lowe HL; Lock S; Iles N; Bell H; Ngai Y; Elgar G; Szallasi Z; Schwarz RF; Herrero J; Stewart A; Quezada SA; Peggs KS; Van Loo P; Dive C; Lin CJ; Rabinowitz M; Aerts HJWL; Hackshaw A; Shaw JA; Zimmermann BG; ; ; Swanton C
Nature; 2017 Apr; 545(7655):446-451. PubMed ID: 28445469
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
Eur Urol; 2024 May; ():. PubMed ID: 38811314
[TBL] [Abstract][Full Text] [Related]
12. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
Transl Res; 2024 Jun; ():. PubMed ID: 38838851
[TBL] [Abstract][Full Text] [Related]
13. Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer.
Zhang X; Feng R; Xu Y; Yang L; Xie F; Yang H; Wang S; Peng Y; Liu M; Wang C; Wang S
Gland Surg; 2024 May; 13(5):684-696. PubMed ID: 38845832
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 May; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
15. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
17. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
18. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
19. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
